Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.

@article{Cantarovich2008BenefitON,
  title={Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction.},
  author={Marcelo Cantarovich and Heather Ross and Jos{\'e} Mar{\'i}a Ariz{\'o}n and Miguel Gomez and Lynn Straatman and Josefina Or{\'u}s and Luis M Alonso-Pulp{\'o}n and Beatriz D{\'i}az Molina and Shaohua Wang and E. J. S. Lage and Mar{\'i}a Generosa Crespo and Nicol{\'a}s Manito and Jonathan G. Howlett and Haissam A Haddad},
  journal={Transplantation},
  year={2008},
  volume={85 7},
  pages={992-9}
}
BACKGROUND For cyclosporine (CsA), 2-hr postdose level (C2) is the best single time point predictor of the area under the curve and a critical measure for effective dosing. The therapeutic CsA microemulsion (Neoral) C2 range in de novo heart transplant patients remains to be determined. PURPOSE The purpose of this study was to determine the efficacy of CsA C2 monitoring in de novo heart transplant patients receiving basiliximab induction. METHODS This prospective, multicenter, randomized… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression

Transplant international : official journal of the European Society for Organ Transplantation • 2015
View 1 Excerpt

The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2010

Similar Papers

Loading similar papers…